UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drugBusiness live – latest updatesAstraZeneca has struck a $1bn (£773m) deal to buy a Belgian biotech company that specialises in cancer immunotherapies, the latest in a string of acquisitions that also yielded positive results for a late-stage rare disease drug on Monday.EsoBiotec, a small privately held firm founded four years ago in Mont-Saint-Guibert, develops in-vivo cell therapies that empower the immune system to attack cancers, and could offer many more patients access to cell therapy treatments provided in minutes rather than weeks. Continue reading...
AstraZeneca is acquiring Belgian biotech firm, EsoBiotec, for up to $1 billion to expand its cancer immunotherapy capabilities. EsoBiotec develops in-vivo CAR-T cell therapies that offer a quicker and less complex alternative to traditional cell therapies, potentially making treatments more accessible. The deal is part of AstraZeneca's ongoing strategy of targeted acquisitions to strengthen its drug portfolio. In related news, AstraZeneca's Imfinzi treatment was approved in the EU for a type of lung cancer, and a drug acquired from Amolyt Pharma showed positive results in treating a rare endocrine disease.
